Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live

Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccinatio...

Full description

Bibliographic Details
Main Authors: Desmond Curran, Brandon J. Patterson, Desiree Van Oorschot, Philip O. Buck, Justin Carrico, Katherine A. Hicks, Bruce Lee, Barbara P. Yawn
Format: Article
Language:English
Published: Taylor & Francis Group 2019-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
vaccination
cost-effectiveness
revaccination
recombinant zoster vaccine
booster
older adults
Online Access:http://dx.doi.org/10.1080/21645515.2018.1558689

Similar Items

Similar Items